CD69 and neoplasm: We also observed higher frequency of activated CD69+ CD44+ CD8+ splenic T cells in tumor-bearing mice treated with the combination of 5AZADC and ADU-S100 compared to those treated with either single agent (Fig. 7b, c; Supplementary Fig. 6b).